VYNE Therapeutics to Participate at the LifeSci Partners 11th Annual Corporate Access Event

Rhea-AI Summary

VYNE Therapeutics announced its participation in one-on-one investor meetings at the LifeSci Partners 11th Annual Corporate Access Event, scheduled virtually from January 5-7, 2022. The Company aims to enhance patient care through innovative therapies targeting immuno-inflammatory conditions. Key products include FMX114 for mild-to-moderate atopic dermatitis and a range of BET domain inhibitors for various conditions. Investors are encouraged to visit VYNE's website for further updates and disclosures.

News Market Reaction – VYNE

+10.78%

+10.78% Session move

In the trading session that priced this news, VYNE gained 10.78%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BRIDGEWATER, N.J., Jan. 03, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that management will participate in one-on-one investor meetings at the LifeSci Partners 11^th Annual Corporate Access Event, to be held virtually January 5-7, 2022.

About VYNE Therapeutics Inc.

VYNE’s mission is to improve the lives of patients by developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions. The Company’s unique and proprietary pipeline includes FMX114 for the potential treatment of mild-to-moderate atopic dermatitis and access to a library of bromodomain & extra-terminal (BET) domain inhibitors in both topical and oral forms for the potential treatment of major immuno-inflammatory conditions and rare skin diseases.

For more information about VYNE Therapeutics Inc. or its investigational products, visit www.vynetherapeutics.com. VYNE may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor VYNE’s website in addition to following its press releases, filings with the U.S. Securities and Exchange Commission, public conference calls, and webcasts.

Investor Relations:

John Fraunces
LifeSci Advisors, LLC
917-355-2395
jfraunces@lifesciadvisors.com

Tyler Zeronda
Chief Financial Officer
VYNE Therapeutics
908-458-9106
Tyler.Zeronda@vynetx.com

 

FAQ

What is VYNE Therapeutics doing at the LifeSci Partners event?

VYNE Therapeutics will participate in one-on-one investor meetings at the LifeSci Partners 11th Annual Corporate Access Event from January 5-7, 2022.

What therapies does VYNE Therapeutics focus on?

VYNE Therapeutics develops therapies for immuno-inflammatory conditions, including FMX114 for atopic dermatitis and BET domain inhibitors.

When is the LifeSci Partners Corporate Access Event taking place?

The LifeSci Partners Corporate Access Event is scheduled for January 5-7, 2022.

How can I learn more about VYNE Therapeutics and its products?

For more information about VYNE Therapeutics and its investigational products, visit their website at www.vynetherapeutics.com.

What is the stock symbol for VYNE Therapeutics?

The stock symbol for VYNE Therapeutics is VYNE, and it is listed on Nasdaq.